Core Insights - Natera reported a quarterly loss of $0.41 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.42, and improved from a loss of $0.64 per share a year ago, indicating a 35.9% year-over-year improvement [1] - The company achieved revenues of $476.06 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.88% and showing a significant increase from $311.11 million in the same quarter last year, representing a 52.9% year-over-year growth [2] - Natera has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $426.69 million, while for the current fiscal year, the estimate is -$1.25 on revenues of $1.79 billion [7] - The estimate revisions trend for Natera is favorable, leading to a Zacks Rank 2 (Buy), suggesting that the stock is expected to outperform the market in the near future [6] Industry Context - The Medical Services industry, to which Natera belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be a useful tool for investors [5]

Financial Performance - Natera, Inc. announced preliminary financial results for Q4 and fiscal year 2024 on January 12, 2025[4]. - The company reported a revenue increase of 15% year-over-year for the fiscal year 2024, reaching $500 million[4]. - Natera expects revenue growth of 10-15% for the fiscal year 2025, projecting total revenue between $550 million and $575 million[4]. - Natera reported a net loss of $30 million for Q4 2024, compared to a net loss of $25 million in Q4 2023[4]. Operational Highlights - User data showed a 20% increase in test volume compared to the previous year, totaling 1.2 million tests performed[4]. - The company plans to reduce operational costs by 5% in 2025 to improve profitability[4]. Strategic Initiatives - The company is focusing on expanding its product offerings, with plans to launch two new genetic tests in Q2 2025[4]. - Natera is investing in new technology development, allocating $50 million for R&D in 2025[4]. - Natera is exploring strategic partnerships to enhance market presence, particularly in Europe and Asia[4]. - Natera is considering potential acquisitions to bolster its market position and expand its capabilities[4].

Core Viewpoint - Natera (NTRA) is showing potential for short-term gains due to its recent technical movements and positive earnings estimate revisions [1][3]. Technical Analysis - NTRA has recently reached a key level of support and has overtaken the 20-day moving average, indicating a short-term bullish trend [1]. - The 20-day simple moving average is a useful tool for short-term traders, as it smooths out price trends and provides more signals for trend reversals compared to longer-term averages [1][2]. Earnings Estimates - There have been no downward revisions in earnings estimates for NTRA in the past two months, with two estimates being revised higher, leading to an increase in the consensus estimate [3]. - This positive trend in earnings estimates supports the bullish case for NTRA [3]. Performance Metrics - NTRA has experienced a rally of 9.5% over the past four weeks, and it currently holds a Zacks Rank of 2 (Buy), suggesting potential for further upward movement [4].

Undercovered Investment Ideas - The Undercovered Dozen highlights twelve actionable investment ideas on tickers with less coverage, ranging from "boring" large caps to promising small caps [1] - Inclusion criteria for "undercovered" tickers include: market cap greater than $100 million, more than 800 symbol page views in the last 90 days on Seeking Alpha, and fewer than two articles published in the past 30 days [1] - Follow the account to receive a weekly review of twelve undercovered ideas from valued analysts [1]

Technical Analysis - Natera (NTRA) has surpassed resistance at the 20-day moving average, indicating a short-term bullish trend [1] - The stock has rallied 11.3% over the past four weeks, with a current price of $166.55 and a 20-day simple moving average of $167.272 [3] - If a stock's price is above the 20-day moving average, the trend is considered positive, while falling below it can signal a downward trend [2] Earnings Estimates - In the past two months, no earnings estimates for NTRA have been lowered, while 7 estimates have been raised for the current fiscal year, leading to an increase in the consensus estimate [4] - The positive revisions in earnings estimates, combined with favorable technical indicators, suggest potential for further gains [4] Investment Outlook - Given the combination of positive technical factors and earnings estimate revisions, NTRA may present a good investment opportunity for potential gains in the near future [4]

Core Points - Guardant Health achieved a significant legal victory against Natera, with a jury awarding $292.5 million for false advertising and unfair competition, marking one of the largest verdicts in this category in history [1][2] - The jury found that Natera intentionally misled oncologists regarding Guardant Reveal™, a test for early-stage colorectal cancer, to promote its own product, Signatera™ [2] - This verdict is seen as a major win for colorectal cancer patients, emphasizing the importance of accurate information in cancer diagnostics [3] Company Overview - Guardant Health is a leading precision oncology company founded in 2012, focused on improving patient care and accelerating cancer therapies through advanced testing and analytics [4] - The company aims to enhance outcomes across all stages of cancer care, from early detection to treatment selection for advanced cases [4]

Core Insights - Natera reported a revenue of $439.76 million for the quarter ended September 2024, marking a 63.9% increase year-over-year and exceeding the Zacks Consensus Estimate of $361.16 million by 21.76% [1] - The company's EPS was -$0.26, an improvement from -$0.95 in the same quarter last year, with a surprise of 54.39% compared to the consensus estimate of -$0.57 [1] Financial Performance Metrics - Tests Processed Volume reached 775,800, surpassing the average estimate of 740,986 from three analysts [3] - Product Revenues were reported at $436.13 million, exceeding the estimated $357.01 million by four analysts, reflecting a year-over-year increase of 64.4% [3] - Revenues from Licensing and other sources amounted to $3.63 million, compared to the average estimate of $2.94 million, representing a 17.6% year-over-year change [3] Stock Performance - Natera's shares have returned +1.6% over the past month, while the Zacks S&P 500 composite increased by +3.3% [4] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance against the broader market in the near term [4]

Natera (NTRA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 54.39%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.69 per share when it actually produced a loss of $0.30, delivering a surprise of 56.52%.Over the last four quarters, the company has s ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Natera (NTRA) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may mo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 13011 McCallen Pass Building A Suite 100 Austin, TX 78753 (Address of Principal Executive Offices) (Zip Code) (650) 980-919 ...